|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
These results establish a model for the BIG3-PHB2 interaction and an entry for drug discovery for breast cancer.
|
31421830 |
2019 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
|
28929359 |
2018 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Stapled BIG3 helical peptide ERAP potentiates anti-tumour activity for breast cancer therapeutics.
|
28500289 |
2017 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer.
|
19496786 |
2009 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
These results establish a model for the BIG3-PHB2 interaction and an entry for drug discovery for breast cancer.
|
31421830 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Stapled BIG3 helical peptide ERAP potentiates anti-tumour activity for breast cancer therapeutics.
|
28500289 |
2017 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer.
|
19496786 |
2009 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Brefeldin A-inhibited guanine nucleotide-exchange protein 3 (BIG3) interacts with and inhibits the tumor suppressor function of prohibitin-2 (PHB2), and recent in vivo studies have demonstrated that the BIG3-PHB2 interaction is a promising target for breast cancer therapy.
|
31421830 |
2019 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Furthermore, we investigated the function and potential mechanism of a novel highly expressed lncRNA, lnc-KIAA1244-2, and found that its expression is associated with tumor size, N classification and clinical stage.
|
31235759 |
2019 |
|
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Lung nodule growth rate (a biomarker for lung cancer), emphysema/air trapping (a biomarker for chronic obstructive pulmonary disease), and coronary artery calcification (a biomarker for cardiovascular disease) are imaging biomarkers of early stages of the Big-3 that can be acquired with low-dose computed tomography (CT).
|
30550403 |
2019 |
|
Chronic Obstructive Airway Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lung nodule growth rate (a biomarker for lung cancer), emphysema/air trapping (a biomarker for chronic obstructive pulmonary disease), and coronary artery calcification (a biomarker for cardiovascular disease) are imaging biomarkers of early stages of the Big-3 that can be acquired with low-dose computed tomography (CT).
|
30550403 |
2019 |
|
Nodule
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Lung nodule growth rate (a biomarker for lung cancer), emphysema/air trapping (a biomarker for chronic obstructive pulmonary disease), and coronary artery calcification (a biomarker for cardiovascular disease) are imaging biomarkers of early stages of the Big-3 that can be acquired with low-dose computed tomography (CT).
|
30550403 |
2019 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lung nodule growth rate (a biomarker for lung cancer), emphysema/air trapping (a biomarker for chronic obstructive pulmonary disease), and coronary artery calcification (a biomarker for cardiovascular disease) are imaging biomarkers of early stages of the Big-3 that can be acquired with low-dose computed tomography (CT).
|
30550403 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lnc-KIAA1244-2 could promote the cell proliferation of ESCC cells and might be a potent therapeutic target for ESCC.
|
31235759 |
2019 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lung nodule growth rate (a biomarker for lung cancer), emphysema/air trapping (a biomarker for chronic obstructive pulmonary disease), and coronary artery calcification (a biomarker for cardiovascular disease) are imaging biomarkers of early stages of the Big-3 that can be acquired with low-dose computed tomography (CT).
|
30550403 |
2019 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Lung nodule growth rate (a biomarker for lung cancer), emphysema/air trapping (a biomarker for chronic obstructive pulmonary disease), and coronary artery calcification (a biomarker for cardiovascular disease) are imaging biomarkers of early stages of the Big-3 that can be acquired with low-dose computed tomography (CT).
|
30550403 |
2019 |
|
Lymphatic Metastasis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further clinical data analysis demonstrated that a decreased expression of circ-KIAA1244 in plasmas was negatively correlated with TNM stage and lymphatic metastasis, and a shorter overall survival time of GC patients.
|
30236115 |
2018 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study revealed a GC-tissues-derived circ-KIAA1244 could serve a novel circulating biomarker for detection of GC.
|
30236115 |
2018 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study revealed a GC-tissues-derived circ-KIAA1244 could serve a novel circulating biomarker for detection of GC.
|
30236115 |
2018 |